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Background: TOP2A encodes for topoisomerase IIα, a nuclear enzyme that controls DNA topological structure and
cell cycle progression. This enzyme is a marker of cell proliferation in normal and neoplastic tissues; however, little
information is available about its expression in prostate cancer (PCa).
Methods: Immunohistochemistry (IHC) was automated using mouse monoclonal antibody against TOP2A (clone
SWT3D1; DAKO, Carpenteria, CA, USA) at dilution 1:800 and Flex Plus detection system in autostainer 48Ultra
(DAKO). FISH was performed using TOP2A (17q21)/ CEP17 probe kit (Kreateck Biotechnology, San Diego, CA, USA).
Biochemical and pathological data from 193 patients with PCa were retrieved for the analysis, whose significance
was considered when p < 0.05. Also, fractal analysis was performed in a subset of 20 randomly selected cases.
Results: TOP2A protein expression correlated with higher Gleason scores and higher levels of preoperative PSA
(p = 0.018 and p = 0.011). Patients with higher levels of TOP2A presented shorter biochemical recurrence-free
survival (BRFS) (p = 0.001). In multivariate analysis, we found that TOP2A remained an independent prognostic factor
of BRFS, with a relative risk of 1.98 (p = 0.001; 95% CI, 1.338–2.93); thus, cases that expressed high levels of this
enzyme had a shorter BRFS compared with TOP2A-negative or TOP2A-low cases. No alterations in TOP2A gene
status nor correlation between FISH and IHC results were observed. Concerning fractal analysis, patients who
expressed higher levels of TOP2A have angiolymphatic invasion and presented higher Gleason scores (p = 0.033
and p = 0.025, respectively). Also, patients with higher expression of TOP2A presented shorter BRFS (p = 0.001).
Conclusions: This is the first study to perform TOP2A protein and gene digital assessment and fractal analysis in
association with BRFS in a large series of PCa. Also, we show that TOP2A gene copy number alterations are not
observed in this type of tumor. So, higher protein expression of TOP2A is not related to gene amplification in PCa.
Furthermore, TOP2A protein assessment has prognostic importance and, due to its relation with poor outcome,
TOP2A IHC evaluation in the biopsy can represent an important tool for selecting the most suitable surgical and
clinical approach for patients with PCa.
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Two homologous but distinct isoforms of type II human
topoisomerases have been identified: the 1531 amino acid
170 kDa DNA topoisomerase IIα (TOP2A) and the 1621
amino acid 180 kDa DNA topoisomerase IIβ (TOP2B)
encoded by the highly related TOP2A and TOP2B genes,
respectively [1,2]. TOP2A plays important roles in DNA
synthesis and transcription, as well as chromosomal segre-
gation during mitosis [1]. Beyond its physiological func-
tions, TOP2A is reported to be a sensitive and specific
marker of actively proliferating cells (in the late S, G2 and
M-phases of the cell cycle), which suggests the importance
of its investigation in cancer [1].
Among men, cancer of the prostate, lung and bron-
chus, and colorectum accounted for 52% of all newly
diagnosed cancers in 2010 [3]. Generally, prostate cancer
(PCa) alone accounts for 28% (217,730) of incident cases
in men [3]. This disease exhibits considerable variability
in clinical behavior [4]. Many (if not most) PCa are clin-
ically indolent, while others are clinically aggressive, be-
coming metastatic and lethal [4]. For localized PCa,
treatment options range from active surveillance to
decisive surgical excision (radical prostatectomy) or radi-
ation therapy [4]. Increasingly, there is a need for prog-
nostic biomarkers to accurately stratify patients for
appropriate risk-adapted therapy [4]. TOP2A is clearly a
proliferation marker and proliferation measurements in
PCa have repeatedly been shown to provide prognostic
information [4-11]. However, little information is avail-
able about TOP2A expression in prostate carcinoma [6].
In the present study we showed the prognostic import-
ance of TOP2A in PCa by correlating immunohisto-
chemical (IHC) and fluorescent in situ hybridization
(FISH) with well-established prognostic values in PCa
and with patients’ biochemical and pathological data and
biochemical recurrence-free survival (BRFS). To the best
of our knowledge, this is the first study to perform
TOP2A protein and gene digital assessment and fractal
analysis in association with BRFS and other clinical data
in a large series of PCa.
Patients and methods
Tumor samples and biochemical and pathological data
Formalin-fixed paraffin-embedded tissue specimens from
patients with PCa who underwent radical prostatectomy
and were diagnosed at A.C. Camargo Cancer Hospital
(Sao Paulo, Brazil) between 1991 and 2009 were retrieved
for the study. As a result, a tissue microarray (TMA) con-
taining 193 prostatic adenocarcinomas was constructed.
Inclusion criteria were the availability of suitable paraffin
blocks for IHC and follow-up information.
All PCa were graded based on the Gleason system by
2 independent pathologists at A.C. Camargo Cancer
Hospital in a blind and consecutive manner to ensureadequate diagnosis and grade. The TNM staging system
was used to describe the extent of PCa in patients (based
on the AJCC Cancer Staging Manual, Seventh Edition,
2010, Springer New York, Inc.). TNM stages IIA and IIB
were considered TNM stage II. All samples in this study
were collected prior to hormone treatment or radiother-
apy. The following biochemical and pathological para-
meters were recorded: preoperative PSA, Gleason score,
TNM stage, lymph node status, angiolymphatic invasion,
extraprostatic extension, margin status and seminal vesicle
(SV) invasion. The study was approved by the ethics com-
mittee of our institution (Research Ethics Committee of
A. C. Camargo Cancer Hospital) under process number
1473/10.
Tissue microarray construction
Representative areas of prostatic adenocarcinoma were
marked on hematoxylin- and-eosin-stained sections and
cylinders 1 mm in diameter were punched from selected
areas of the donor paraffin blocks (Beecher Instruments,
Silver Spring, MD, USA). Each tumor was sampled twice
in the TMA block that was cut 3 μm thick for the IHC
and FISH studies.
Immunohistochemistry (IHC)
IHC staining was performed using automated stand-
ard procedures (Flex Plus detection system, DAKO,
Carpenteria, CA, USA) and mouse monoclonal antibody
against TOP2A (SWT3D1 clone; DAKO, Carpenteria,
CA, USA) at dilution 1:800. Specific standardized proto-
col supplied by the manufacturer was followed. Testis
was used as positive control, and omission of primary
antibody was applied as negative control.
Immunohistochemical analysis
All slides were digitalized using Aperio System (Vista, CA,
USA), and the images provided by the software were
exhibited on an LCD monitor under contrast, focus, satur-
ation, and white balance standardization. Automated
image quantification was performed using the nuclei
quantification algorithm, which associates staining inten-
sity with percentage of stained cells and generates a final
score ranging from 0 (negative) to 1 (weak positive), 2
(moderate positive), or 3 (strong positive). Then, numer-
ical scores were exported to a Microsoft Excel (Seattle,
WA, USA) file for further statistical analysis.
Fluorescent In situ Hybridization (FISH)
FISH was performed using TOP2A (17q21)/CEP17
probe kit (Kreateck Biotechnology USA Inc, San Diego,
CA, USA) and DAPI counterstaining. Fluorescent slides
were assessed in a fluorescent microscope concerning
chromosome 17 polyssomy and TOP2A gene amplifica-
tion or deletion.
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20 PCa samples were randomly selected from our set to
perform the fractal analysis. The histochemically stained
cells were selected for capturing images and target stained
cells were microphotographed in an isolated condition,
with minimal contact or overlap of neighboring cells.
Cell images were captured with a Nikon D90 SLR
digital camera 12.9 mega pixels DX-format and a file for-
mat of JPEG with an image size of 1,424-4,288 con-
nected to the photoport attachment of a Nikon diaphot
300 inverted phase contrast microscope. Cells were
observed with a 10×/20m wide field adjustable eyepiece
at 400× magnification. Original images were stored in a
TIFF format from JPEG in order to perform a back-
ground color correction using Micrografix picture pub-
lisher 8 windows graphic software. The images were
then imported into Adobe Photoshop version CS5 for
Macintosh. From each image, the three most suitable
histochemically stained cells for fractal analysis were
chosen. These three chosen cells were then cropped out
of their original images with a 65 × 65 pixel frame that
was centered on the chosen stained cell. Utilizing the
quick selection tool in Photoshop (with settings of 100%
hardness, 8% spacing, auto-enhance turned off, and a se-
lection size of three pixels) secondary histochemically
stained cells present in the targeted 65 × 65 pixel image
were selected and cropped out, resulting in one stained
cell per new created image without artifacts (i.e., frag-
ments of other cells). Captured images were stored in
BMP format, with a bit depth of 24, and were then
binarized by the Benoit 1.3 fractal analysis software
(TruSoft International Inc., St. Petersburg, FL) to calcu-
late the fractal dimension of the cells.
For the fractal dimension calculation, box dimension
was taken as an appropriate approximation of fractal di-
mension. In the present study due to the original JPEG
dimensions and size of the cells, the box sizes were
set at 65, and the fractal dimension was computed by
using the Benoit software (TruSoft International Inc.,











Absence 75 (39.5)Statistical analysis
Mann–Whitney test was used to calculate the correlation
between numerical variables. X2 test was used to evaluate
differences in frequency of categorical-variable groups.
Spearman’s rank correlation was used to analyze the cor-
relation between continuous variables. Kaplan-Meier and
log-rank tests were used to evaluate survival rates before
biochemical recurrence concerning expression of TOP2A
with BRFS (based on the increase in PSA, defined as PSA
level > 0.2 ng/ml). The level of statistical significance was
set to 0.05 for these tests. Statistical analyses were per-
formed using SPSS, version 11.0 (USA).Results
Patients and clinical data
102 patients (52.84%) presented Gleason score of 6, and
the remaining 91 cases (47.16%) presented Gleason score
between 8–10. 95 patients (49.22%) presented TNM
stage II; 86 (44.55%) presented stage III; and 8 patients
(6.23%) presented TNM stage IV. The median preopera-
tive PSA level was 8.6 ng/ml. Other clinicopathological
features are summarized in Table 1.
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higher TNM stages (p < 0.001), positive margin (p =
0.002), SV (p < 0.001), angiolymphatic invasion (p = 0.019),
and positive lymph nodes (p = 0.003) presented shorter
BRFS. The median of BRFS in our set of PCa patients was
30.49 months, ranging from 0.3 to 108.88 months.IHC and FISH signals
IHC sharp and specific nuclear staining for TOP2A was
observed in tumor cells as shown in Figure 1. Orange
signals for TOP2A gene and green signals for centro-
meric region of chromosome 17 were observed; however,
no numerical alterations in TOP2A gene and chromo-
some 17 were noticed in any tumor sample (Figure 2).Figure 1 Immunostaining for TOP2A in prostate cancer observed at 2
1+ staining (C); and negative staining (D).TOP2A and biochemical and pathological data
Patients who expressed higher levels of TOP2A presented
higher Gleason scores and higher levels of preoperative
PSA (p = 0.018 and p = 0.011, respectively). Also, patients
with higher expression of TOP2A presented shorter BRFS
(p = 0.001; Figure 3), as shown in Table 2. On the other
hand, there was no difference between tumors with
Gleason score 7(3 + 4) and tumors with Gleason score
7(4 + 3) concerning TOP2A IHC expression.
TOP2A remained as an independent prognostic factor
for BRFS in the multivariate analysis, with a relative risk of
1.98 (p = 0.001; 95% CI, 1.338 – 2.93). Thus, cases that
expressed higher TOP2A presented shorter BRFS com-
pared with TOP2A-negative or TOP2A-lower cases. The
presence of SV invasion (hazard ratio = 3.038; p < 0.001;00 magnification showing 3+ staining (A); 2+ staining (B);
Figure 2 Examples of fluorescent in situ hybridization for
TOP2A gene (orange) and chromosome 17 (green) showing no
copy number alteration.
Figure 3 Biochemical recurrence-free survival curves showing lower s
TOP2A protein.
Table 2 Association between TOP2A expression and
biochemical recurrence-free survival
TOP2A intensity Median (months) p*
1+ (weak) 60.230 0.001
2+ (moderate) 29.375
3+ (strong) 16.743
* Statistically significant p values inferior to 0.05.
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prognostic factor for BRFS (Table 3).
Fractal analysis
Median of TOP2A intensity evaluated in a subset of
20 randomly selected cases was 1.754. Patients who
expressed higher levels of TOP2A (TOP2A intensity
≥ 1.754) presented angiolymphatic invasion and higher
Gleason scores (p = 0.033 and p = 0.025, respectively).
Also, patients with higher expression of TOP2A (TOP2A
intensity ≥ 1.754) presented shorter BRFS (p = 0.001;
Figure 4).
Discussion
Analysis of the cell kinetics of cancer cells in situ (for
example, by Ki-67 antigen expression or mitotic counts)urvival rates of those cases which expressed high levels of





TOP2A (higher intensities) 1.98 1.338 – 2.93 0.001
Seminal vesicle invasion (presence) 3.038 1.755 – 5.256 <0.001
* Statistically significant p values inferior to 0.05.
de Resende et al. Journal of Translational Medicine 2013, 11:36 Page 6 of 9
http://www.translational-medicine.com/content/11/1/36has been increasingly used to evaluate prognosis and/or
biological behavior of various human malignancies [12].
TOP2A is a nuclear enzyme that controls DNA topo-
logical structure and cell cycle progression [13]. It mainly
supports DNA decoiling, chromosome segregation during
anaphase of the cell cycle, and DNA replication, by creat-
ing a DNA-linked protein gate through which another in-
tact DNA duplex passes [14]. This enzyme is a marker of
cell proliferation in normal and neoplastic tissues [15]. In
malignant cells, overexpression of TOP2A protein might
reflect not only the proliferative advantage of these cells,
but also qualitative alterations caused by malignant trans-
formation and dedifferentiation [12]. The IHC method for
in situ determination of TOP2A has been extensively vali-
dated and shown to reflect closely the exact enzyme activ-
ity in formalin-fixed paraffin-embedded human tissues,Figure 4 Biochemical recurrence-free survival curves concerning fract
lower survival rates of those who expressed higher levels of TOP2A pleading to the prognostic and predictive importance of this
test in other neoplasms [16].
This is the first study that brings together a gene and
protein assessment of TOP2A in the largest series of
prostate adenocarcinoma. Also, fractal image analysis
was performed in order to confirm digital assessment in
a subset of randomly selected cases. Furthermore, for
the first time we bring an association between all these
data and BRFS curve.
Concerning IHC pattern of expression for TOP2A,
positive nuclear staining was found. Also, additional dif-
fuse weak cytoplasmic staining was seen in some cases,
as Faggad et al. [17] and Gotlieb et al. [18] also reported
in their respective studies. Corroborating most works on
literature, we found that the expression of TOP2A was
an indicative of poor prognosis. Patients who expressed
higher levels of its protein had higher Gleason scores,
higher levels of preoperative PSA, and shorter BRFS. In-
deed, high proliferation rates in cancers are typically
associated with worse clinical outcome [4]. According to
Faggad et al. [17], one explanation for the shorter sur-
vival rate associated with elevated TOP2A levels could
be an enhancement of tumor cell proliferation, which
results in increased tumor aggressiveness. In theal analysis of a subset of 20 randomly selected cases showing
rotein.
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dependent prognostic factor for BRFS, along with the
presence of SV invasion.
Increased TOP2A is a common, though not specific, oc-
currence in malignant cells [19]. According to O’Connor
et al. [19], there are several mechanisms to explain this
upregulation in these cells. First, both pRB and p53 are
negative regulators of topoisomerase IIα, and both are well
known to be inactivated or deleted in malignant cells [14].
Inactivated or deleted pRB or p53 would be expected to
increase the expression of this enzyme [19]. Another pos-
sible mechanism for the overexpression of TOP2A is the
amplification of a coding gene such as that for HER2/neu
[19]. Both HER2/neu and TOP2A reside on the long arm
of chromosome 17 and amplification of one gene locus
could simultaneously overexpress both of these genes
[19]. In the present study, we did not find any alterations
on TOP2A status in FISH. Schindlbeck et al. [14] found
that TOP2A amplification was not significant for outcome
in women with primary breast cancer, protein expression
only (IHC) was related to outcome in those patients.
According to this work, protein expression might be more
relevant than TOP2A amplification or deletion in predict-
ing the outcome of breast cancer patients that received
anthracycline-based chemotherapy [14]. In another study
of our group [20], TOP2A amplification did not correlate
with FISH results in soft tissue sarcomas. According to
Werneck et al. [20], increased TOP2A expression does
not appear to result solely from gene amplification. The
explanation for this finding is still unclear; it might be due
to posttranscriptional regulation [20]. This corroborates
studies on other solid tumors, like breast cancer [21,22]
and gastric carcinoma [23]. Werneck et al. [20] suggested
that gene amplification and protein expression should be
evaluated separately when the prognostic or predictive
value of TOP2A is examined in any neoplasia.
High levels of TOP2A expression are generally asso-
ciated with high levels of cellular proliferation and poor
histologic differentiation of tumors [24]. The relation-
ship between overexpression of this enzyme and poor
prognosis has been reported in different neoplasias, like
breast cancer [19], urothelial bladder carcinoma [12],
larynx cancer [15], bladder cancer [24], and ovarian can-
cer [17]. On the other hand, although most studies on
literature correlates high levels of TOP2A expression
with poorer survival rates and more aggressive tumors,
there are studies showing the opposite. Bredel et al. [25]
concluded that high expression of TOP2A and Ki-67
appeared to be associated with prolonged survival in
glioblastoma patients. In a recent work, Schindlbeck
et al. [14] showed that TOP2A IHC positivity predicted
lower risk of metastases and death in breast cancer
patients. Yan et al. [26] demonstrated that high TOP2A
expression was correlated with better disease-freesurvival for postoperative non-small cell lung cancer
(NSCLC) patients who received adjuvant chemotherapy.
One reason for these discrepant results is that these
patients received adjuvant chemotherapy and high grade
tumors tend to present better response to this type of
therapy. Yan et al. [26] postulated that adjuvant chemo-
therapy might overcome the adverse biology of cancers
that expressed high levels of TOP2A protein. According
to this latter work, NSCLC patients with high expression
of the enzyme might be able to obtain more benefits
from adjuvant chemotherapy than those with low ex-
pression, which emphasizes the predictive importance of
TOP2A for such patients [26].
Proliferation measurements in PCa have generally
been done by studying the Ki-67 molecule, which is
present in actively cycling cells [5]. IHC for Ki-67 in PCa
has been shown to have prognostic importance (tumors
with high Ki-67 expression tend to have a poorer prog-
nosis and high tumor Ki-67 value also appear to predict
tumor recurrence after radical prostatectomy) [5]. Since
TOP2A has been found to correlate well with Ki-67 in a
number of human diseases, Willman et al. [5] suggested
that similar prognostic information might be obtained
by TOP2A IHC, with an advantage that the enzyme is
the target of drugs being used for treating PCa patients.
However, there are few works in the literature correlat-
ing TOP2A and clinicopathological parameters of PCa.
Sullivan et al. [7] showed that the expression of this en-
zyme increased with both stage and grade, and advan-
cing stage was the stronger predictor of TOP2A
expression. Willman et al. [5] and Hasby et al. [8], in
their respective works, demonstrated that the prostatic
carcinomas with the highest expression of the enzyme
were more poorly differentiated and had the highest
Gleason scores. Hughes et al. [6] showed that TOP2A
expression increased with increasing Gleason score and
with hormone insensitivity. Murphy et al. [9] showed
that increased TOP2A copy number was associated with
adverse clinical features, including high Gleason score,
high stage, androgen resistant, HER2 amplification, and
decreased survival under multivariate analysis. In a re-
cent study, Karnes et al. [10] demonstrated that the time
for PCa patients to develop systemic progression (SP)
was significantly associated with TOP2A protein expres-
sion: higher 5-year SP rates were observed in patients
with higher protein levels of the enzyme. Ida et al. [11]
showed that TOP2A protein expression was predictive
of SP and death in PCa patients with Gleason score ≥7
treated surgically, especially in PCa without ERG overex-
pression. Malhotra et al. [4] demonstrated that a tri-
marker proliferation index (which included Ki-67, TOP2A,
and E2F1) provided improved prognostic performance in
PCa; it predicted biochemical recurrence after radical
prostatectomy.
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score 7(4 + 3) have higher chances of presenting biochem-
ical recurrence compared to patients with Gleason score
7(3 + 4). In addition, they also showed that the primary
Gleason pattern 4 remained as an independent prognostic
factor for the occurrence of biochemical recurrence in PCa
patients [27]. Although the clinical difference between
patients from both groups of Gleason 7 [(3 + 4) and (4 +
3)] is largely known, we found no difference in TOP2A ex-
pression between them. We suppose that TOP2A may not
be related (at least not by itself) to early stages of carcino-
genesis and morphological undifferentiating, which may
result in further aggressive tumor biological behavior.
However, when analyzing all Gleason scores there was a
significant difference in TOP2A expression, showing that
this protein may come up in more discrepant lesions. Fur-
thermore, the absolute relation between the presence of
TOP2A in tumors of patients with biochemical recurrence
is an evidence that this protein is related to late stages of
tumor development.
Besides its important role as a proliferation marker, as
shown above, TOP2A is also the molecular target of sev-
eral chemotherapy agents, including anthracyclines such
as doxorubicin and etoposide [19]. These cytotoxic
agents bind the DNA topoisomerase II complex and in-
hibit the relegation of DNA [19]. This converts TOP2A
into a physiologic toxin and introduces high levels of
permanent double-stranded breaks, which are detected
by proteins ensuring genomic integrity [28]. As a result
of the activation of this machinery, the cells with abun-
dant DNA breaks are eliminated by apoptosis [28]. The
sensitivity or resistance of a malignant cell to these anti
tumor drugs, also called topo II poisons, is proportional
to the level of TOP2A expression [11,14]. In PCa, there
are several phase II trials using etoposide or docetaxel in
combination with other chemotherapy agents to treat
androgen-sensitive metastatic prostate carcinoma and
hormone-refractory PCa, with promising results [29-31].
The biological behavior of PCa still challenges research-
ers and urologists. While some patients present indolent
disease with no need for treatment, others present aggres-
sive disease with inevitable progression. Therefore a good
prognostic and predictive marker of adjuvant and target
therapies would be of great utility. In this sense, TOP2A is
emerging as an important molecular target for many
anticancer drugs, and several experimental works have
clearly showed that cellular sensitivity to this enzyme is
dependent on its high levels [30]. In conclusion, we found
that higher expression of TOP2A protein in PCa patients
is a strong indicative of poor prognosis. Also, since
TOP2A is a target for many anti-neoplastic drugs, the
IHC evaluation of this marker in routine practice can be
a powerful tool for selecting appropriately aggressive
therapies (use of adjuvant chemotherapy), specific targettherapies, and the most suitable surgery approach in
order to improve outcome of patients with prostate can-
cer. Also, we show for the first time that TOP2A gene
copy number alterations are not observed in this type of
tumor. So, higher protein expression of TOP2A is not
related to gene amplification in PCa. Furthermore,
TOP2A protein assessment has prognostic importance
and, due to its relation with poor outcome, TOP2A IHC
evaluation in the biopsy can represent an important tool
for selecting the most suitable surgical and clinical ap-
proach for patients with PCa.
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